Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Karyopharm Therapeutics's EBIT per Share for the
three
months ended in Mar. 2026 was €-0.34.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €-9.31.
During the past 3 years, the average EBIT per Share Growth Rate was 31.70% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 22.10% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 15.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Karyopharm Therapeutics's EBIT per Share or its related term are showing as below:
STU:25K0'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -32.3 Med: 8 Max: 31.7
Current: 31.7
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Karyopharm Therapeutics was 31.70% per year. The lowest was -32.30% per year. And the median was 8.00% per year.
STU:25K0's 3-Year EBIT Growth Rate is ranked better than 70.79% of 1171
companies
in the Biotechnology industry
Industry Median: 15.5
vs STU:25K0: 31.70
Karyopharm Therapeutics (STU:25K0) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Karyopharm Therapeutics EBIT per Share Related Terms
Karyopharm Therapeutics EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-9.31
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Karyopharm Therapeutics (STU:25K0) has a EBIT per Share of €-9.31 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Karyopharm Therapeutics and its competitors. According to the industry distribution chart, Karyopharm Therapeutics ranks #342 out of 1171 companies in the Biotechnology industry, placing it in the top 29.2%.
Is Karyopharm Therapeutics' EBIT per Share too high?
Karyopharm Therapeutics' current EBIT per Share is €-9.31. Based on the distribution chart, Karyopharm Therapeutics ranks #342 out of 1171 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Karyopharm Therapeutics has a GF Score™ of 60/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Karyopharm Therapeutics' EBIT per Share compare to TNYA and HUMA?
According to the Biotechnology industry distribution chart, Karyopharm Therapeutics ranks #342 out of 1171 companies for EBIT per Share. This puts Karyopharm Therapeutics in the upper half of its industry. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,171 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Karyopharm Therapeutics and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Karyopharm Therapeutics's current EBIT per Share is €-9.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Karyopharm Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Karyopharm Therapeutics (STU:25K0) is currently considered Modestly Overvalued. The stock's GF Value™ is €5.22, compared to a current price of €6.20 — trading 18.8% above its estimated fair value. The current EBIT per Share is €-9.31. Karyopharm Therapeutics' overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Karyopharm Therapeutics (STU:25K0), the current EBIT per Share is €-9.31 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Karyopharm Therapeutics (STU:25K0) Overvalued in 2026?
Based on GuruFocus' analysis, Karyopharm Therapeutics stock appears to be overvalued.
The current stock price of €6.20 is trading 18.8% above its estimated GF Value™ of €5.22.
GuruFocus considers Karyopharm Therapeutics to be Modestly Overvalued.
Key valuation signals for STU:25K0:
EBIT per Share: €-9.31
GF Value™: €5.22 vs. price of €6.20 (18.8% above fair value)
No single metric tells the full story. See the STU:25K0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
60GF Score
Get the complete analysis for STU:25K0
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:25K0 has been successfully added to your 
